Logo image of EVGN

EVOGENE LTD (EVGN) Stock Fundamental Analysis

NASDAQ:EVGN - Nasdaq - IL0011050551 - Common Stock - Currency: USD

1.48  +0.07 (+4.94%)

After market: 1.49 +0.01 (+0.68%)

Fundamental Rating

1

Overall EVGN gets a fundamental rating of 1 out of 10. We evaluated EVGN against 572 industry peers in the Biotechnology industry. EVGN has a bad profitability rating. Also its financial health evaluation is rather negative. EVGN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EVGN has reported negative net income.
In the past year EVGN has reported a negative cash flow from operations.
EVGN had negative earnings in each of the past 5 years.
In the past 5 years EVGN always reported negative operating cash flow.
EVGN Yearly Net Income VS EBIT VS OCF VS FCFEVGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -58.62%, EVGN perfoms like the industry average, outperforming 41.78% of the companies in the same industry.
Industry RankSector Rank
ROA -58.62%
ROE N/A
ROIC N/A
ROA(3y)-43.55%
ROA(5y)-37.7%
ROE(3y)-115.12%
ROE(5y)-86.46%
ROIC(3y)N/A
ROIC(5y)N/A
EVGN Yearly ROA, ROE, ROICEVGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 68.90%, EVGN belongs to the top of the industry, outperforming 81.47% of the companies in the same industry.
EVGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVGN Yearly Profit, Operating, Gross MarginsEVGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

EVGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for EVGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EVGN Yearly Shares OutstandingEVGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
EVGN Yearly Total Debt VS Total AssetsEVGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -11.26, we must say that EVGN is in the distress zone and has some risk of bankruptcy.
EVGN has a Altman-Z score of -11.26. This is in the lower half of the industry: EVGN underperforms 75.52% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.26
ROIC/WACCN/A
WACC6.29%
EVGN Yearly LT Debt VS Equity VS FCFEVGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

EVGN has a Current Ratio of 1.09. This is a normal value and indicates that EVGN is financially healthy and should not expect problems in meeting its short term obligations.
EVGN has a Current ratio of 1.09. This is amonst the worse of the industry: EVGN underperforms 86.36% of its industry peers.
A Quick Ratio of 1.03 indicates that EVGN should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.03, EVGN is not doing good in the industry: 86.36% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.03
EVGN Yearly Current Assets VS Current LiabilitesEVGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

EVGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.32%, which is quite impressive.
EPS 1Y (TTM)41.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%178.55%

3.2 Future

Based on estimates for the next years, EVGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.07% on average per year.
EVGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 57.25% yearly.
EPS Next Y-2%
EPS Next 2Y13.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year38.71%
Revenue Next 2Y57.25%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

EVGN Yearly Revenue VS EstimatesEVGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
EVGN Yearly EPS VS EstimatesEVGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EVGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVGN Price Earnings VS Forward Price EarningsEVGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVGN Per share dataEVGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as EVGN's earnings are expected to grow with 13.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.07%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

EVGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOGENE LTD

NASDAQ:EVGN (3/7/2025, 8:22:32 PM)

After market: 1.49 +0.01 (+0.68%)

1.48

+0.07 (+4.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/bmo
Earnings (Next)05-21 2025-05-21/bmo
Inst Owners7.68%
Inst Owner Change-87.91%
Ins Owners1.56%
Ins Owner ChangeN/A
Market Cap7.95M
Analysts82.5
Price Target8.29 (460.14%)
Short Float %0.3%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.15%
Min EPS beat(2)-27.16%
Max EPS beat(2)16.86%
EPS beat(4)3
Avg EPS beat(4)4.03%
Min EPS beat(4)-27.16%
Max EPS beat(4)17.44%
EPS beat(8)7
Avg EPS beat(8)18.07%
EPS beat(12)9
Avg EPS beat(12)12.8%
EPS beat(16)11
Avg EPS beat(16)7.85%
Revenue beat(2)1
Avg Revenue beat(2)-13.1%
Min Revenue beat(2)-38.22%
Max Revenue beat(2)12.01%
Revenue beat(4)3
Avg Revenue beat(4)1.12%
Min Revenue beat(4)-38.22%
Max Revenue beat(4)17.37%
Revenue beat(8)5
Avg Revenue beat(8)26.79%
Revenue beat(12)8
Avg Revenue beat(12)67.45%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.03%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-17.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.06
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.11
EYN/A
EPS(NY)-3.17
Fwd EYN/A
FCF(TTM)-3.87
FCFYN/A
OCF(TTM)-3.8
OCFYN/A
SpS1.39
BVpS-0.81
TBVpS-3.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.9%
FCFM N/A
ROA(3y)-43.55%
ROA(5y)-37.7%
ROE(3y)-115.12%
ROE(5y)-86.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.15%
Cap/Sales 5.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 1.03
Altman-Z -11.26
F-Score3
WACC6.29%
ROIC/WACCN/A
Cap/Depr(3y)37.84%
Cap/Depr(5y)34.18%
Cap/Sales(3y)58.32%
Cap/Sales(5y)72.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.62%
EPS Next Y-2%
EPS Next 2Y13.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%178.55%
Revenue Next Year38.71%
Revenue Next 2Y57.25%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.69%
EBIT Next 3Y15.29%
EBIT Next 5YN/A
FCF growth 1Y32.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.81%
OCF growth 3YN/A
OCF growth 5YN/A